首頁 > 市場調查報告書 > 醫療設備

心血管設備

市場調查報告書

商品編碼

1606506

全球單腔起搏器市場 - 2024-2031

Global Single-Chamber Pacemaker Market - 2024-2031

出版日期: 2024年12月04日 | 出版商:

DataM Intelligence | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球單腔起搏器市場規模達到22.0億美元，預計2031年將達到27.7億美元，2024-2031年預測期間複合年成長率為3.0%。

單腔起搏器是一種向一個心腔（即心房或心室）提供電脈衝的裝置。這種類型的起搏器對於大多數患有心率緩慢（心搏過緩）或任何其他限制其維持適當心臟速率能力的節律紊亂的患者最有幫助。它包括一個脈衝產生器（帶有電路的電池）和一個用於將電訊號傳遞到感興趣的室的導線。對於心律不規則不需要多個心室之間同步的患者，臨床醫師認為單心室系統比雙心室或雙心室系統更簡單。微創技術提供可靠、經濟高效的心律管理。

市場動態：

驅動程式和限制

心血管疾病盛行率上升

心律不整數量的增加，特別是緩慢心律不整或心臟傳導阻滯等疾病，大大促進了單腔起搏器市場的全球擴張。老年人口的增加進一步增加了心血管疾病的發生率，因為老年人更多地患有與心律相關的疾病。

單腔起搏器可以有效管理與節律相關的心臟疾病，這對於為有需要的患者提供心臟功能至關重要。人們對心臟問題的早期診斷和治療認知的提高也推動了這種趨勢的發展。大多數時候，單腔起搏器足夠單一，可以在資源匱乏的地區提供有效、可靠、但具有成本效益的治療，保證其市場佔有率。

例如，根據英國心臟基金會的數據，心血管疾病仍然是全世界男性和女性死亡的主要原因。到 2023 年，全球約 6,200 億人口中，有 80 億人患有心臟病和血管疾病。全球每年約有 600 億人被診斷出罹患心臟病或循環系統疾病。據建議，每 13 名患者中就有 1 名患有心臟或循環系統疾病。世界上約有三分之一的死亡是由心血管疾病造成的；到 2021 年，全球將有超過 205 億人死亡，即每天有 56,000 人喪生，幾乎每 1 又 1/2 秒就有 1 人喪生。

高級替代方案的可用性

起搏器，用於更廣泛的心律管理。這些設備將電脈衝同步到心臟的多個心室，已被證明對患有複雜心律不整或心臟衰竭的患者更有益。因此，相對於單腔起搏器，醫療保健提供者可能更喜歡先進的選擇，特別是在醫療保健預算較高的已開發經濟市場。

此外，採用這些設備的其他障礙是與起搏器的植入和持續維護相關的高價格，在一些資源有限的地區缺乏足夠熟練的專業人員，導致成本限制。人們也擔心感染、導線脫位和設備故障等併發症，特別是對於來自資源有限環境的患者及其醫生。

Single-chamber pacemaker is a device that provides electrical impulses to one heart chamber, namely the atrium or the ventricle. This type of pacemaker is most helpful to most patients suffering from slow heart rate (bradycardia) or any other rhythm disorder that limits its ability to maintain an adequate rate in the heart. It comprises a pulse generator-a battery with circuitry-and a lead for electrical signals passing to the chamber of interest. Clinicians consider single-chamber systems simpler devices than dual-chamber or biventricular systems for patients whose rhythm irregularities do not require synchronization between multiple chambers. Minimal-invasive technology provides reliable, cost-effective heart rhythm management.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Cardiovascular Diseases

Rising numbers of arrhythmias, particularly such conditions as bradyarrhythmias or heart block, significantly contribute to the global expansion of the single-chamber pacemaker market. Rising elderly population further increases the incidence of cardiovascular conditions as older adults suffer more from the rhythm-related disorder of the heart.

Effective management of the rhythm-related heart disorders was made possible with single-chamber pacemakers, which became essential in providing heart function to patients in need. They also have been fueled by a greater demand for awareness of a patient's early diagnosis and treatment in cardiac problems. Most times, single-chamber pacemakers are single enough to provide effective and reliable, but cost-effective therapy in resource-strapped regions, guaranteeing their share in the market.

For instance, according to British Heart Foundation, cardiovascular disease remains the leading cause of death in both men and women throughout the world. In the year of 2023 the world's population is 8 billion out of those approximately 620 Billion are suffering from cardiac and vascular illnesses everywhere across the globe. Every year approximately sixty Billion individuals in the globe will be diagnosed with heart or circulatory disease. It has been suggested that one out of every 13 patients has heart or circulatory ailments. Cardiovascular diseases are responsible for roughly 1 out of 3 deaths in the world; these accounted for - over 20.5 Billion deaths worldwide in 2021 - which is 56,000 lost lives every day or almost one every 1 and 1/2 second.

Availability of Advanced Alternatives

pacemakers, for more extensive heart rhythm management. These devices synchronize electrical impulses into several chambers of the heart, which has be proved to be more beneficial for patients with complex arrhythmias or heart failure. Hence, healthcare providers would probably favor advanced options over single-chamber pacemakers, especially in developed economic markets that have higher healthcare budgets.

Moreover, other impediments in the adoption of these devices would be high prices associated with the implantation and ongoing maintenance of the pacemaker where there is a lack of sufficient skilled professionals in some resource-limited areas that lead to constraints in costing. There are also fears of complications such as those of infection, lead dislocation, and malfunction of the devices, particularly among patients and their physicians from resource-constrained settings.

Segment Analysis

The global single-chamber pacemaker market is segmented based on product type, indication, end user, and region.

Product type:

Implantable single-chamber pacemakers segment is expected to dominate the single-chamber pacemaker market share

The implantable single-chamber pacemakers segment holds a major portion of the single-chamber pacemaker market share and is expected to continue to hold a significant portion of the single-chamber pacemaker market share during the forecast period.

An implantable single-chamber pacemaker is a primary source in the single-chamber pacemakers for managing long-term cardiac rhythms with an ideal solution for disorders such as bradycardia and heart block. It is surgically implanted under the skin with a lead connected to either the atrium or ventricle for heart rate regulation. Due to their ability to read and respond to the electrical activity of the heart, they are critical for the patient who requires constant rhythm management. It is mainly a long-term solution for heart rhythm disorders.

The main reason these devices have energy demand is their durability, better extensions, and utility in terms of features such as MRI compatibility and remote monitoring. These devices gained an entry into developed and emerging markets, thus being established as essential in this segment in the single-chamber pacemaker market.

End User:

Hospitals segment is the fastest-growing segment in the single-chamber pacemaker market share

The hospitals segment is the fastest-growing segment in the single-chamber pacemaker market share and is expected to hold the market share over the forecast period.

Hospitals will constitute some of the main areas in terms of the Global Single-Chamber Pacemaker Market: diagnosis, implantation, and follow-up care for pacemaker patients. They provide necessary infrastructure such as specialized cardiac care units and skilled medical personnel, including cardiologists and electrophysiologists, trained to manage pacemaker procedures. Hospitals are often the first point of contact for patients with arrhythmias or other cardiac complaints, triggering early diagnosis and timely intervention.

Furthermore, hospitals propel the advanced technologies and treatment protocols adoption, ensuring that the patients receive the latest pacemaker models enhanced with better functionality. Additionally, hospitals sustain growth in the market by taking part in clinical trials that help advance pacemaker technology and offering training programs that uphold the growth of expertise in the implanting and management of pacemaker devices.

Geographical Analysis

North America is expected to hold a significant position in the Single-Chamber Pacemaker market share

North America holds a substantial position in the Single-Chamber Pacemaker market and is expected to hold most of the market share due to increasing incidences of cardiovascular disorders and new arrhythmias due to research developments, in the wake of a growing elderly population. Highly advanced health care infrastructure, along with greater access to high-end technologies, contribute significantly to the growth of the market. Also, strong healthcare reimbursement policies in countries such as the United States and Canada further make pacemaker therapies more accessible. Continued collaboration on research and development by prominent market players with favourable regulatory approvals can also further boost market growth in this region.

For instance, in July 2023, Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generation INGEVITY Pacing Leads. These are thin wires placed inside the heart and connected to an implantable device and allow conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) in connection with a single- or dual-chamber pacemaker.

Europe is growing at the fastest pace in the Single-Chamber Pacemaker market

Europe holds the fastest pace in the Single-Chamber Pacemaker market and is expected to hold most of the market share.

Europe, a convergence of an aging populace and a rise in lifestyle-related heart problems will drive the Single-Chamber Pacemaker Market's growth. The strong public healthcare systems make countries such as Germany, France, and the UK perfect beneficiaries of the growing market of cardiac care. Ongoing improvements in pacemaker technology, to make more compact devices with greater battery life, also play an influential role. Furthermore, the European Union's efforts in fostering new innovations in medical devices and the presence of well-known international medical-device manufacturers contribute to the growth of the market.

For instance, in July 2023, BIOTRONIK announced FDA approval for its suite of Amvia Edge pacemakers and CRT-Ps, the company's new technology for cardiac rhythm management. Introducing innovative patient-centric clinical solutions, it is also the most efficient automated workflow. Amvia Edge is the market's smallest single-chamber MR conditional pacemaker.

Competitive Landscape

The major global players in the single-chamber pacemaker market include Medtronic, Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Osypka Medical GmbH, Lepu Medical Technology, Oscor Inc, Shree Pacetronix Ltd among others.

Emerging Players

The emerging players in the single-chamber pacemaker market include Medico, EPMed, CureMetrix, Zoll Medical and among others.

Key Developments

In November 2024, Abbott recently announced the launch of the AVEIR VR single-chamber ventricular leadless pacemaker, meant for treating patients with slow heart rhythms in India. This pacemaker has already received approval from the Central Drugs Standard Control Organization (CDSCO) in India. It is also US Food and Drug Administration (FDA) approved.
Why Purchase the Report?
Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global single-chamber pacemaker market report would provide approximately 70 tables, 65 figures, and 184 pages.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product type
3.2. Snippet by Indication
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the Prevalence of Cardiovascular Diseases
4.2. Restraints
- 4.2.1. Availability of Advanced Alternatives
4.3. Opportunity
- 4.3.1. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
- 6.1.2. Market Attractiveness Index, By Product type
6.2. Implantable Single-Chamber Pacemakers*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. External Single-Chamber Pacemakers

7. By Indication

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 7.1.2. Market Attractiveness Index, By Indication
7.2. Bradycardia*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Atrial Fibrillation
7.4. Heart Block
7.5. Sick Sinus Syndrome
7.6. Others

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers (ASCs)
8.4. Cardiac Clinics

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
- 9.3.7. South America
  - 9.3.7.1. Introduction
  - 9.3.7.2. Key Region-Specific Dynamics
  - 9.3.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
  - 9.3.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  - 9.3.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  - 9.3.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.7.6.1. Brazil
  - 9.3.7.6.2. Argentina
  - 9.3.7.6.3. Rest of South America
- 9.3.8 Asia-Pacific
  - 9.3.8.1 Introduction
  - 9.3.8.2 Key Region-Specific Dynamics
  - 9.3.8.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
  - 9.3.8.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  - 9.3.8.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  - 9.3.8.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.8.6.1 China
  - 9.3.8.6.2 India
  - 9.3.8.6.3 Japan
  - 9.3.8.6.4 South Korea
  - 9.3.8.6.5 Rest of Asia-Pacific
- 9.3.9 Middle East and Africa
  - 9.3.9.1 Introduction
  - 9.3.9.2 Key Region-Specific Dynamics
  - 9.3.9.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
  - 9.3.9.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  - 9.3.9.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Medtronic*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Boston Scientific Corporation
11.3. Abbott Laboratories
11.4. Biotronik SE & Co. KG
11.5. MicroPort Scientific Corporation
11.6. LivaNova PLC
11.7. Osypka Medical GmbH
11.8. Lepu Medical Technology
11.9. Oscor Inc
11.10. Shree Pacetronix Ltd

LIST NOT EXHAUSTIVE